Tag: Alzheimer’s

Associations consistent across different psychiatric conditions, for Alzheimer disease and all other dementias

Announcement comes shortly after Aduhelm maker Biogen cut the price of the drug by about half, from $56,000 to $28,000 a year

The Self-Administered Gerocognitive Examination detects the conversion from mild cognitive impairment to dementia sooner than the MMSE

Drug shows promise in clearing brain plaques believed to play a role in Alzheimer disease

Higher baseline coffee consumption also linked to slower Aβ-amyloid accumulation during a 126-month study period as shown on brain MRI scans

Grounds insufficient to offer aducanumab for moderate, advanced Alzheimer dementia or patients without biomarker evidence of brain ß-amyloid

Phase 1 trial will include 16 patients ages 60 to 85 years who have early, symptomatic Alzheimer disease but are otherwise in good health

New premium will be $170.10 a month, and the $21.60 boost is the biggest increase ever in dollar amount, but not in percentage terms

After adjustment for multiple variables, widespread pain appeared to increase subsequent risk

Low amyloid burden and favorable cognitive outcomes seen with DPP-4i use in Alzheimer disease-related cognitive impairment with diabetes